Top

Archives of Gynecology and Obstetrics

Published in:

01-04-2015 | Maternal-Fetal Medicine

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms

Authors: Valeria C. Sandrim, Ana C. T. Palei, Nibia Eleuterio, Jose E. Tanus-Santos, Ricardo C. Cavalli

Published in: Archives of Gynecology and Obstetrics | Issue 4/2015

Abstract

Introduction

Vascular endothelial growth factor (VEGF) is relevant for healthy pregnancy, and abnormalities in VEGF functions have been associated with hypertensive disorders of pregnancy. Our group recently demonstrated that VEGF genetic polymorphisms affect the susceptibility to preeclampsia (PE).

Objective

Therefore, in this study our aim is to examine whether VEGF polymorphisms affect the antihypertensive responses in women with PE.

Methods

We studied 113 white PE women who were stratified according to blood pressure levels after antihypertensive treatment (46 responsive, R group and 67 non-responsive, NR group). We then compared the frequencies of two VEGF genetic polymorphisms (C-2578A and G-634C) between R and NR groups.

Results

We found no significant differences in genotype or allele distributions between R and NR groups (P > 0.05). In addition, no difference was observed in overall distribution of haplotypes (P > 0.05).

Conclusion

Our data suggest that VEGF polymorphisms do not affect responsiveness to the antihypertensive therapy in PE.

Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884–891CrossRefPubMed

Anonymous (2000) Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1–S22CrossRef

Awata T, Inoue K, Kurihara S et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639CrossRefPubMed

Chaiworapongsa T, Romero R, Kim YM et al (2005) Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 17:3–18CrossRefPubMed

Crawford DC, Nickerson DA (2005) Definition and clinical importance of haplotypes. Annu Rev Med 56:303–320CrossRefPubMed

de Vasconcelos D, Izidoro-Toledo TC, Sandrim VC et al (2009) Aldosterone synthase gene polymorphism is not associated with gestational hypertension or preeclampsia. Clin Chim Acta 400:139–141CrossRefPubMed

Demir R, Kayisli UA, Cayli S et al (2006) Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta 27:535–539CrossRefPubMed

Demir R, Kayisli UA, Seval Y et al (2004) Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25:560–572CrossRefPubMed

Demir R, Seval Y, Huppertz B (2007) Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem 109:257–265CrossRefPubMed

10.

Esser S, Wolburg K, Wolburg H et al (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947–959CrossRefPubMedCentralPubMed

11.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMed

12.

Girnita DM, Webber SA, Ferrell R et al (2006) Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82:1774–1780CrossRefPubMed

13.

He H, Venema VJ, Gu X et al (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274:25130–25135CrossRefPubMed

14.

He Y, Smith SK, Day KA et al (1999) Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13:537–545CrossRefPubMed

15.

Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22CrossRefPubMedCentralPubMed

16.

Johnson GC, Esposito L, Barratt BJ et al (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29:233–237CrossRefPubMed

17.

Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709CrossRefPubMedCentralPubMed

18.

Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324–328CrossRefPubMed

19.

Kroll J, Waltenberger J (1998) VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252:743–746CrossRefPubMed

20.

Lambrechts D, Storkebaum E, Morimoto M et al (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383–394CrossRefPubMed

21.

Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658CrossRefPubMedCentralPubMed

22.

Podymow T, August P (2008) Update on the use of antihypertensive drugs in pregnancy. Hypertension 51:960–969CrossRefPubMed

23.

Prior SJ, Hagberg JM, Paton CM et al (2006) DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 290:H1848–H1855CrossRefPubMed

24.

Roberts JM, Gammill HS (2005) Preeclampsia: recent insights. Hypertension 46:1243–1249CrossRefPubMed

25.

Sandrim VC, Coelho EB, Nobre F et al (2006) Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186:428–432CrossRefPubMed

26.

Sandrim VC, de Syllos RWC, Lisboa HR et al (2006) Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189:241–246CrossRefPubMed

27.

Sandrim VC, Palei AC, Cavalli RC et al (2009) Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 15:115–120CrossRefPubMed

28.

Sandrim VC, Palei AC, Luizon MR et al (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 10(1):40–45CrossRefPubMed

29.

Sandrim VC, Yugar-Toledo JC, Desta Z et al (2006) Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 24:2393–2397CrossRefPubMed

30.

Schneider BP, Radovich M, Sledge GW et al (2007) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 20:20

31.

Shahbazi M, Fryer AA, Pravica V et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260–264PubMed

32.

Shen BQ, Lee DY, Zioncheck TF (1999) Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274:33057–33063CrossRefPubMed

33.

Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25–35CrossRefPubMed

34.

Sibai BM (2008) Intergenerational Factors. A Missing Link for Preeclampsia, Fetal Growth Restriction, and Cardiovascular Disease? Hypertension 7:7

35.

Sibai BM, Barton JR (2007) Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 196:514CrossRefPubMed

36.

Smith GC, Crossley JA, Aitken DA et al (2007) Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 109:1316–1324CrossRefPubMed

37.

Venkatesha S, Toporsian M, Lam C et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649CrossRefPubMed

38.

Walker JJ (2000) Pre-eclampsia. Lancet 356:1260–1265CrossRefPubMed

39.

Zachary I (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375–C1386PubMed

40.

Zhou Y, McMaster M, Woo K et al (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160:1405–1423CrossRefPubMedCentralPubMed

Title: Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms
Authors: Valeria C. Sandrim
Ana C. T. Palei
Nibia Eleuterio
Jose E. Tanus-Santos
Ricardo C. Cavalli
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 4/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3475-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms

Abstract

Introduction

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2015

Diastolic blood pressure increase is a risk indicator for pre-eclampsia

Second trimester amniotic fluid retinol in patients developing preeclampsia

Response to: Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome; an evidence-based approach

Surgical and systemic management of endometrial cancer: an international survey

What should be the goal for future development of colposcopy? Cons and pros of sensitivity and specificity

Evaluation of indication-specific genuine stress urinary incontinence procedures in a pelvic floor center